New Ultrasound-Guided clot treatment aims to save lungs and hearts

NCT ID NCT06310018

Terminated Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a procedure that uses ultrasound and a catheter to deliver a low dose of a clot-dissolving drug directly to blood clots in the lungs. The goal is to quickly reduce the strain on the heart and improve blood flow, while keeping the risk of serious bleeding low. The trial includes 60 adults with severe but stable pulmonary embolism and signs of heart stress.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tissue plasminogen activator (tPA) - a clot-dissolving drug
What this could lead to: If successful, this could offer a safer, lower-dose way to treat dangerous blood clots in the lungs, reducing heart strain and bleeding complications.
What could go wrong: This is an early, single-arm study with only 60 participants, so results may not apply broadly. The trial is currently suspended, and bleeding risks remain a concern.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY EMBOLISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure pulmonary embolism Ventricular Dysfunction, Right

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY EMBOLISM RIGHT VENTRICULAR DYSFUNCTION RIGHT VENTRICULAR FAILURE

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.